Edgewise Therapeutics Appoints Christopher Martin to Board

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Edgewise Therapeutics ( (EWTX) ) has shared an announcement. Edgewise Therapeutics announced the appointment of Christopher Martin to its Board of Directors on November 19, 2025. Martin, a seasoned biotech executive, previously served as Chief Commercial Officer at Verona Pharma, which was acquired by Merck & Co. His expertise is expected to be instrumental as Edgewise prepares for its first commercial launch in Becker muscular dystrophy and advances its cardiovascular asset to Phase 3. The most recent analyst rating on (EWTX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Edgewise Therapeutics stock, see the EWTX Stock Forecast page. Spark’s Take on EWTX Stock According to Spark, TipRanks’ AI Analyst, EWTX is a Underperform. Edgewise Therapeutics’ overall score reflects significant risks due to its pre-revenue stage and increasing losses. Positive corporate events, including substantial fundraising and promising trial results, offer growth potential. However, the bearish technical indicators and valuation challenges highlight the stock’s high-risk profile typical of early-stage biotech companies. To see Spark’s full report on EWTX stock, click here. More about Edgewise Therapeutics Edgewise Therapeutics is a leading biopharmaceutical company specializing in muscle diseases, focusing on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company is advancing products like sevasemten, EDG-7500, and EDG-15400, which are in various stages of clinical development. Average Trading Volume: 1,012,243 Technical Sentiment Signal: Strong Buy Current Market Cap: $2.37B Find detailed analytics on EWTX stock on TipRanks’ Stock Analysis page.